1. Home
  2. PNI vs AGEN Comparison

PNI vs AGEN Comparison

Compare PNI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco New York Municipal Income Fund II of Beneficial Interest

PNI

Pimco New York Municipal Income Fund II of Beneficial Interest

HOLD

Current Price

$7.00

Market Cap

77.8M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.46

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNI
AGEN
Founded
2002
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.8M
147.4M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
PNI
AGEN
Price
$7.00
$3.46
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
37.3K
744.4K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
4.76%
N/A
EPS Growth
N/A
100.00
EPS
N/A
1.02
Revenue
N/A
$42,877,086.00
Revenue This Year
N/A
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.32
Revenue Growth
N/A
89.95
52 Week Low
$6.43
$2.71
52 Week High
$7.20
$7.34

Technical Indicators

Market Signals
Indicator
PNI
AGEN
Relative Strength Index (RSI) 54.67 48.00
Support Level $6.88 $2.93
Resistance Level $7.10 $4.72
Average True Range (ATR) 0.08 0.24
MACD 0.00 0.01
Stochastic Oscillator 63.99 68.46

Price Performance

Historical Comparison
PNI
AGEN

About PNI Pimco New York Municipal Income Fund II of Beneficial Interest

PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: